Loading…
Biogen Inc. is projected to rise to $227.65 by 2027, a +14% move from its current price of $199.15. BIIB is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/13/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $195.56 | $199.18 | $202.86 | +0.01% |
| Jul 15 | $194.11 | $199.20 | $204.43 | +0.03% |
| Jul 16 | $193.01 | $199.23 | $205.66 | +0.04% |
| Jul 17 | $192.09 | $199.26 | $206.70 | +0.05% |
| Jul 18 | $191.29 | $199.29 | $207.62 | +0.07% |
| Jul 19 | $190.57 | $199.31 | $208.46 | +0.08% |
| Jul 20 | $189.91 | $199.34 | $209.24 | +0.10% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $189.91 | $199.34 | $209.24 | +0.10% |
| Week 2 | $186.31 | $199.53 | $213.69 | +0.19% |
| Week 3 | $183.64 | $199.72 | $217.21 | +0.29% |
| Week 4 | $181.44 | $199.91 | $220.26 | +0.38% |
| Week 5 | $179.55 | $200.10 | $223.01 | +0.48% |
| Week 6 | $177.87 | $200.30 | $225.55 | +0.58% |
| Week 7 | $176.36 | $200.49 | $227.92 | +0.67% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Biogen Inc. is a healthcare company that discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. Its portfolio includes TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis; SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreichs Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, IMRALDI, and FLIXABI biosimilars; LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, CLL, rheumatoid arthritis, two forms of ANCA associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for relapsed or refractory diffuse large B cell lymphoma; and other anti CD20 therapies.
Biogen has collaboration and license agreements with Merz Therapeutics, Alkermes Pharma Ireland Limited, Denali Therapeutics Inc., UCB, Eisai Co., Ltd., Genentech, Neurimmune SubOne AG, Ionis Pharmaceuticals, Samsung Bioepis, and Sage Therapeutics, along with collaborations with Stoke Therapeutics for Dravet syndrome and Dayra Therapeutics for oral macrocyclic peptides, among others. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Biogen Inc. is currently priced at $200.36 per share, and its market capitalization stands at $29.58B with a rank of 455. These figures place the stock in a defined market position while the long term price outlook points toward material appreciation, as reflected in the year by year forecast.
The forecast shows an upward trajectory in average price across years, beginning near the current level and moving higher through 2050.
A major floor 13.5% below — a decisive break under it would weaken the trend.
The nearest floor, 5.2% below — buyers have tended to step in here.
The nearest ceiling, 8.8% above — a clean break opens room to run.
A major ceiling 15.2% above — clearing it would confirm fresh momentum.
Key BIIB support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BIIB market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $202.52 | Sell | $202.30 | Sell |
| MA 10 | $208.72 | Sell | $204.20 | Sell |
| MA 20 | $203.76 | Sell | $203.22 | Sell |
| MA 50 | $197.49 | Buy | $198.03 | Buy |
| MA 100 | $191.21 | Buy | $191.43 | Buy |
| MA 200 | $179.11 | Buy | $181.19 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 47.00 | Neutral |
| Stoch RSI (14) | 1.11 | Buy |
| CCI (20) | -49.17 | Neutral |
| Williams %R (14) | -89.92 | Info |
| MACD (12,26,9) | -1.39 | Sell |
| ROC (12) | 0.99 | Buy |
| Bollinger %B (20,2) | 0.34 | Neutral |
| Stochastic %K (14) | 10.08 | Buy |
| TRIX (15) | 0.27 | Buy |
| Awesome (5,34) | 2.65 | Buy |
| Ultimate (7,14,28) | 34.86 | Neutral |
| Momentum (10) | -2.81 | Sell |
| Aroon Osc (25) | 56.00 | Buy |
| Hull MA (9) | 196.81 | Buy |
| ADX (14) | 13.85 | Neutral |
| ATR (14) | 3.55 | Info |
The near term technical picture is bullish. The RSI14 reads 50, and the stock trades above the SMA50 of $196.81 while the SMA200 sits at $178.54, signaling constructive momentum.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $164.42 | $199.15 | $244.49 | 0% | Neutral | |
| $186.46 | $227.65 | $290.57 | +14% | Neutral | |
| $194.82 | $242.33 | $317.69 | +22% | Bullish | |
| $207.47 | $262.05 | $350.86 | +32% | Bullish | |
| $222.95 | $285.41 | $389.03 | +43% | Bullish | |
| $247.94 | $321.28 | $444.84 | +61% | Bullish | |
| $297.43 | $389.76 | $547.34 | +96% | Bullish | |
| $322.98 | $427.70 | $608.40 | +115% | Bullish | |
| $333.92 | $446.59 | $642.86 | +124% | Bullish | |
| $347.29 | $468.86 | $682.43 | +135% | Bullish | |
| $539.37 | $759.50 | $1,158.48 | +281% | Bullish | |
| $824.12 | $1,244.58 | $2,034.94 | +525% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $164.42 | $199.15 | $237.71 | +0.00% |
| August 2026 | $170.90 | $200.01 | $239.09 | +0.43% |
| September 2026 | $171.47 | $201.65 | $242.96 | +0.82% |
| October 2026 | $174.10 | $205.59 | $249.35 | +1.95% |
| November 2026 | $171.62 | $203.36 | $248.02 | -1.08% |
| December 2026 | $167.77 | $199.45 | $244.49 | -1.92% |
Click any year to see its month-by-month BIIB forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect BIIB to range from $164.42 to $244.49 through 2026. The $199.15 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The BIIB price prediction for 2027 points to an average of $227.65 (low $186.46, high $290.57) — a potential gain of +14% on today's $199.15. Price action looks broadly range-bound.
In 2028, BIIB is projected to trade between $194.82 and $317.69, averaging $242.33 — a potential gain of +22% from today's $199.15. That is up +6% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Biogen Inc.'s 2029 outlook centres on $262.05, within a $207.47 to $350.86 range. That is up +8% on the projected 2028 average. That marks a +32% change versus current levels. Momentum favours further upside here.
By 2030, BIIB could reach as high as $389.03, with a base case around $285.41 and support toward $222.95 — roughly +43% from $199.15. Buyers look set to stay in control over this stretch.
Expect BIIB to range from $247.94 to $444.84 through 2031. The $321.28 average target implies a +61% move from current prices. That is up +13% on the projected 2030 average. Momentum favours further upside here.
The BIIB price prediction for 2032 points to an average of $389.76 (low $297.43, high $547.34) — a potential gain of +96% on today's $199.15. Buyers look set to stay in control over this stretch.
In 2033, BIIB is projected to trade between $322.98 and $608.40, averaging $427.70 — a potential gain of +115% from today's $199.15. That is up +10% on the projected 2032 average. Momentum favours further upside here.
Biogen Inc.'s 2034 outlook centres on $446.59, within a $333.92 to $642.86 range. That is up +4% on the projected 2033 average. That marks a +124% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, BIIB could reach as high as $682.43, with a base case around $468.86 and support toward $347.29 — roughly +135% from $199.15. Momentum favours further upside here.
Expect BIIB to range from $539.37 to $1,158.48 through 2040. The $759.50 average target implies a +281% move from current prices. That is up +62% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The BIIB price prediction for 2050 points to an average of $1,244.58 (low $824.12, high $2,034.94) — a potential gain of +525% on today's $199.15. Momentum favours further upside here.
Investing $1,000 in BIIB today (≈ 5.021341 BIIB) could be worth
$6,249.44
+$5,249.44 (+525%) by 2050 · US Dollar
Based on the average projected BIIB price of $1,244.58 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BIIBwould be worth at today's price.
$1,000 invested in BIIB on Jul 10, 2025 (≈ 7.389344 BIIB) would be worth
$1,471.59
+$471.59 (+47.2%) today · 1.47× · US Dollar
Based on a BIIB entry price of $135.33 vs. today's $199.15.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $216.12 | $921.48 | -7.9% |
| 1 month ago | $194.24 | $1,025.28 | +2.5% |
| 3 months ago | $172.97 | $1,151.36 | +15.1% |
| 6 months ago | $185.63 | $1,072.83 | +7.3% |
| 1 year ago | $135.33 | $1,471.59 | +47.2% |
| All time (5.0y) ago | $352.06 | $565.67 | -43.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BIIB forecast.
Our base-case forecast reaches $400.00 around 2033.
Implied market cap at $400.00: $59.05B
Over the longer horizon, the forecast projects a rising average price from $200.36 in 2026 to $290.27 in 2030 and up to $1,273.54 by 2050, with a max price projection of $2,101.53 in 2050. The implied returns rise from 0% in 2026 to 535.6% by 2050, with consistent bullish sentiment from 2028 onward. Notable midterm steps include 2027 average $230.58 and 2028 average $244.49, followed by stronger gains through 2032 and beyond.
These are estimates, not guarantees, and actual results may differ based on market conditions and company performance.
Tap a question to reveal the answer.
In 2030 the forecast shows a min of $225.90, an avg of $290.27, and a max of $397.58, with an ROI of 44.9% and bullish sentiment.
The long term forecast indicates rising averages from $200.36 in 2026 to $1,273.54 in 2050, with multiple years showing positive ROI up to 535.6%. The near term also suggests bullish odds after 2026, but these are estimates and not guarantees.
Yes. The 2031 forecast shows an average of $325.90, with a 2030 average of $290.27 and 2032 average of $396.80, indicating the potential to surpass $300 on the way to higher targets.
The 2040 forecast projects a min of $545.52, an average of $773.72, and a max of $1,189.19, with an ROI of 286.2 and bullish sentiment.
For 2050 the forecast shows a min of $834.89, an average of $1,273.54, and a max of $2,101.53, with an ROI of 535.6 and bullish sentiment.
Biogen Inc. Community Discussion
0Share your Biogen Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.